342 related articles for article (PubMed ID: 22308557)
1. A prospective, multicentre, randomized, double-blind, placebo-controlled trial of onabotulinumtoxinA to treat plantarflexor/invertor overactivity after stroke.
Dunne JW; Gracies JM; Hayes M; Zeman B; Singer BJ;
Clin Rehabil; 2012 Sep; 26(9):787-97. PubMed ID: 22308557
[TBL] [Abstract][Full Text] [Related]
2. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of OnabotulinumtoxinA 400 Units in Patients with Post-Stroke Upper Limb Spasticity: Final Report of a Randomized, Double-Blind, Placebo-Controlled Trial with an Open-Label Extension Phase.
Abo M; Shigematsu T; Hara H; Matsuda Y; Nimura A; Yamashita Y; Takahashi K
Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32085529
[TBL] [Abstract][Full Text] [Related]
5. Optimal Muscle Selection for OnabotulinumtoxinA Injections in Poststroke Lower-Limb Spasticity: A Randomized Trial.
Esquenazi A; Wein TH; Ward AB; Geis C; Liu C; Dimitrova R
Am J Phys Med Rehabil; 2019 May; 98(5):360-368. PubMed ID: 31003229
[TBL] [Abstract][Full Text] [Related]
6. Neuronox versus BOTOX for spastic equinus gait in children with cerebral palsy: a randomized, double-blinded, controlled multicentre clinical trial.
Kim K; Shin HI; Kwon BS; Kim SJ; Jung IY; Bang MS
Dev Med Child Neurol; 2011 Mar; 53(3):239-44. PubMed ID: 21087238
[TBL] [Abstract][Full Text] [Related]
7. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity.
Sussman D; Patel V; Del Popolo G; Lam W; Globe D; Pommerville P
Neurourol Urodyn; 2013 Mar; 32(3):242-9. PubMed ID: 22965657
[TBL] [Abstract][Full Text] [Related]
8. Dose response with onabotulinumtoxinA for post-stroke spasticity: a pooled data analysis.
Yablon SA; Brin MF; VanDenburgh AM; Zhou J; Garabedian-Ruffalo SM; Abu-Shakra S; Beddingfield FC
Mov Disord; 2011 Feb; 26(2):209-15. PubMed ID: 20960474
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity.
Kaňovský P; Slawek J; Denes Z; Platz T; Comes G; Grafe S; Pulte I
J Rehabil Med; 2011 May; 43(6):486-92. PubMed ID: 21533328
[TBL] [Abstract][Full Text] [Related]
10. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia.
Marberger M; Chartier-Kastler E; Egerdie B; Lee KS; Grosse J; Bugarin D; Zhou J; Patel A; Haag-Molkenteller C
Eur Urol; 2013 Mar; 63(3):496-503. PubMed ID: 23098762
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of NABOTA in post-stroke upper limb spasticity: a phase 3 multicenter, double-blinded, randomized controlled trial.
Nam HS; Park YG; Paik NJ; Oh BM; Chun MH; Yang HE; Kim DH; Yi Y; Seo HG; Kim KD; Chang MC; Ryu JH; Lee SU
J Neurol Sci; 2015 Oct; 357(1-2):192-7. PubMed ID: 26233808
[TBL] [Abstract][Full Text] [Related]
12. OnabotulinumtoxinA for the Treatment of Poststroke Distal Lower Limb Spasticity: A Randomized Trial.
Wein T; Esquenazi A; Jost WH; Ward AB; Pan G; Dimitrova R
PM R; 2018 Jul; 10(7):693-703. PubMed ID: 29330071
[TBL] [Abstract][Full Text] [Related]
13. Does botulinum toxin type A decrease pain and lessen disability in hemiplegic survivors of stroke with shoulder pain and spasticity?: a randomized, double-blind, placebo-controlled trial.
Marciniak CM; Harvey RL; Gagnon CM; Duraski SA; Denby FA; McCarty S; Bravi LA; Polo KM; Fierstein KM
Am J Phys Med Rehabil; 2012 Dec; 91(12):1007-19. PubMed ID: 23064478
[TBL] [Abstract][Full Text] [Related]
14. Modification of altered ankle motor control after stroke using focal application of botulinum toxin type A.
Tang SF; Hong JP; McKay WB; Tang CW; Wu PH; Chu NK
Clin Neurol Neurosurg; 2012 Jun; 114(5):498-501. PubMed ID: 22480620
[TBL] [Abstract][Full Text] [Related]
15. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
Lipton RB; Varon SF; Grosberg B; McAllister PJ; Freitag F; Aurora SK; Dodick DW; Silberstein SD; Diener HC; DeGryse RE; Nolan ME; Turkel CC
Neurology; 2011 Oct; 77(15):1465-72. PubMed ID: 21956721
[TBL] [Abstract][Full Text] [Related]
16. OnabotulinumtoxinA Improves Pain in Patients With Post-Stroke Spasticity: Findings From a Randomized, Double-Blind, Placebo-Controlled Trial.
Wissel J; Ganapathy V; Ward AB; Borg J; Ertzgaard P; Herrmann C; Haggstrom A; Sakel M; Ma J; Dimitrova R; Fulford-Smith A; Gillard P
J Pain Symptom Manage; 2016 Jul; 52(1):17-26. PubMed ID: 27037050
[TBL] [Abstract][Full Text] [Related]
17. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
Wissel J; Entner T
Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
[TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
19. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke.
Pittock SJ; Moore AP; Hardiman O; Ehler E; Kovac M; Bojakowski J; Al Khawaja I; Brozman M; Kanovský P; Skorometz A; Slawek J; Reichel G; Stenner A; Timerbaeva S; Stelmasiak Z; Zifko UA; Bhakta B; Coxon E
Cerebrovasc Dis; 2003; 15(4):289-300. PubMed ID: 12686794
[TBL] [Abstract][Full Text] [Related]
20. Prospective assessment of tizanidine for spasticity due to acquired brain injury.
Meythaler JM; Guin-Renfroe S; Johnson A; Brunner RM
Arch Phys Med Rehabil; 2001 Sep; 82(9):1155-63. PubMed ID: 11552184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
